Non-trapping PARP degraders are expected to be useful for the treatment of diseases associated with PARP activation (e.g., ischemia–reperfusion injury or neurodegenerative disease) because it does not induce genotoxicity or cell death. This evidence concerns the gene PARP1 and neurodegenerative disease.